Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency.

Boudhabhay I, Frémeaux-Bacchi V, Roumenina LT, Moktefi A, Goujon JM, Matignon M, Caudwell V, Audard V, El Karoui K.

Kidney Int Rep. 2019 May 31;4(9):1354-1358. doi: 10.1016/j.ekir.2019.05.1156. eCollection 2019 Sep. No abstract available.

2.

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.

Roumenina LT, Daugan MV, Noé R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Clec'h BL, Giraldo NA, Merle NS, Sun CM, Verkarre V, Validire P, Selves J, Lacroix L, Delfour O, Vandenberghe I, Thuilliez C, Keddani S, Sakhi IB, Barret E, Ferré P, Corvaïa N, Passioukov A, Chetaille E, Botto M, de Reynies A, Oudard SM, Mejean A, Cathelineau X, Sautès-Fridman C, Fridman WH.

Cancer Immunol Res. 2019 Jul;7(7):1091-1105. doi: 10.1158/2326-6066.CIR-18-0891. Epub 2019 Jun 4.

PMID:
31164356
3.

Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme.

Wiatr M, Merle NS, Boudhabhay I, Poillerat V, Rossini S, Lecerf M, Kaveri SV, Lacroix-Desmazes S, Roumenina LT, Dimitrov JD.

Mol Immunol. 2019 Jul;111:205-208. doi: 10.1016/j.molimm.2019.04.020. Epub 2019 May 10.

4.

Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions.

Merle NS, Boudhabhay I, Leon J, Fremeaux-Bacchi V, Roumenina LT.

Transfus Clin Biol. 2019 May;26(2):116-124. doi: 10.1016/j.tracli.2019.02.008. Epub 2019 Feb 22.

PMID:
30879901
5.

P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner.

Merle NS, Paule R, Leon J, Daugan M, Robe-Rybkine T, Poillerat V, Torset C, Frémeaux-Bacchi V, Dimitrov JD, Roumenina LT.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6280-6285. doi: 10.1073/pnas.1814797116. Epub 2019 Mar 8.

6.

Autoantibodies Against C3b-Functional Consequences and Disease Relevance.

Vasilev VV, Radanova M, Lazarov VJ, Dragon-Durey MA, Fremeaux-Bacchi V, Roumenina LT.

Front Immunol. 2019 Jan 29;10:64. doi: 10.3389/fimmu.2019.00064. eCollection 2019. Review.

7.

Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1.

May O, Merle NS, Grunenwald A, Gnemmi V, Leon J, Payet C, Robe-Rybkine T, Paule R, Delguste F, Satchell SC, Mathieson PW, Hazzan M, Boulanger E, Dimitrov JD, Fremeaux-Bacchi V, Frimat M, Roumenina LT.

Front Immunol. 2018 Dec 20;9:3008. doi: 10.3389/fimmu.2018.03008. eCollection 2018.

8.

Endothelium structure and function in kidney health and disease.

Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT.

Nat Rev Nephrol. 2019 Feb;15(2):87-108. doi: 10.1038/s41581-018-0098-z. Review.

PMID:
30607032
9.

Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H.

Madden I, Roumenina LT, Langlois-Meurinne H, Guichoux J, Llanas B, Frémeaux-Bacchi V, Harambat J, Godron-Dubrasquet A.

Pediatr Nephrol. 2019 Mar;34(3):533-537. doi: 10.1007/s00467-018-4174-1. Epub 2018 Dec 17.

PMID:
30560448
10.

A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein.

Yatime L, Merle NS, Hansen AG, Friis NA, Østergaard JA, Bjerre M, Roumenina LT, Thiel S, Kristensen P, Andersen GR.

Front Immunol. 2018 Nov 29;9:2822. doi: 10.3389/fimmu.2018.02822. eCollection 2018.

11.

Detection of Autoantibodies to Complement Components by Surface Plasmon Resonance-Based Technology.

Noe R, Chauvet S, Togarsimalemath SK, Marinozzi MC, Radanova M, Vasilev VV, Fremeaux-Bacchi V, Dragon-Durey MA, Roumenina LT.

Methods Mol Biol. 2019;1901:271-280. doi: 10.1007/978-1-4939-8949-2_24.

PMID:
30539587
12.

Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.

Chauvet S, Roumenina LT, Aucouturier P, Marinozzi MC, Dragon-Durey MA, Karras A, Delmas Y, Le Quintrec M, Guerrot D, Jourde-Chiche N, Ribes D, Ronco P, Bridoux F, Fremeaux-Bacchi V.

Front Immunol. 2018 Oct 2;9:2260. doi: 10.3389/fimmu.2018.02260. eCollection 2018.

13.

Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.

Merle NS, Grunenwald A, Rajaratnam H, Gnemmi V, Frimat M, Figueres ML, Knockaert S, Bouzekri S, Charue D, Noe R, Robe-Rybkine T, Le-Hoang M, Brinkman N, Gentinetta T, Edler M, Petrillo S, Tolosano E, Miescher S, Le Jeune S, Houillier P, Chauvet S, Rabant M, Dimitrov JD, Fremeaux-Bacchi V, Blanc-Brude OP, Roumenina LT.

JCI Insight. 2018 Jun 21;3(12). pii: 96910. doi: 10.1172/jci.insight.96910. eCollection 2018 Jun 21.

14.

Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis.

Merle NS, Grunenwald A, Figueres ML, Chauvet S, Daugan M, Knockaert S, Robe-Rybkine T, Noe R, May O, Frimat M, Brinkman N, Gentinetta T, Miescher S, Houillier P, Legros V, Gonnet F, Blanc-Brude OP, Rabant M, Daniel R, Dimitrov JD, Roumenina LT.

Front Immunol. 2018 Mar 1;9:179. doi: 10.3389/fimmu.2018.00179. eCollection 2018.

15.

Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum.

Yagi H, Takakura D, Roumenina LT, Fridman WH, Sautès-Fridman C, Kawasaki N, Kato K.

Sci Rep. 2018 Feb 9;8(1):2719. doi: 10.1038/s41598-018-21145-y.

16.

Complement C3 is a novel modulator of the anti-factor VIII immune response.

Rayes J, Ing M, Delignat S, Peyron I, Gilardin L, Vogel CW, Fritzinger DC, Frémeaux-Bacchi V, Kaveri SV, Roumenina LT, Lacroix-Desmazes S.

Haematologica. 2018 Feb;103(2):351-360. doi: 10.3324/haematol.2017.165720. Epub 2017 Nov 16.

17.

[The complement system: a double edge sword in tumor progression].

Daugan M, Noe R, Herman Fridman W, Sautes-Fridman C, Roumenina LT.

Med Sci (Paris). 2017 Oct;33(10):871-877. doi: 10.1051/medsci/20173310019. Epub 2017 Oct 10. Review. French.

18.

A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.

Togarsimalemath SK, Sethi SK, Duggal R, Le Quintrec M, Jha P, Daniel R, Gonnet F, Bansal S, Roumenina LT, Fremeaux-Bacchi V, Kher V, Dragon-Durey MA.

Kidney Int. 2017 Oct;92(4):876-887. doi: 10.1016/j.kint.2017.04.025. Epub 2017 Jul 18.

PMID:
28729035
19.

C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.

Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, Cailliez M, Deschenes G, Fischbach M, Karras A, Nobili F, Pietrement C, Dragon-Durey MA, Fakhouri F, Roumenina LT, Fremeaux-Bacchi V.

Kidney Int. 2017 Nov;92(5):1232-1241. doi: 10.1016/j.kint.2017.04.017. Epub 2017 Jul 14.

PMID:
28712854
20.

Functional and structural insight into properdin control of complement alternative pathway amplification.

Pedersen DV, Roumenina L, Jensen RK, Gadeberg TA, Marinozzi C, Picard C, Rybkine T, Thiel S, Sørensen UB, Stover C, Fremeaux-Bacchi V, Andersen GR.

EMBO J. 2017 Apr 13;36(8):1084-1099. doi: 10.15252/embj.201696173. Epub 2017 Mar 6.

21.

Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.

Marinozzi MC, Roumenina LT, Chauvet S, Hertig A, Bertrand D, Olagne J, Frimat M, Ulinski T, Deschênes G, Burtey S, Delahousse M, Moulin B, Legendre C, Frémeaux-Bacchi V, Le Quintrec M.

J Am Soc Nephrol. 2017 May;28(5):1603-1613. doi: 10.1681/ASN.2016030343. Epub 2017 Jan 17.

22.

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants.

Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16.

23.

Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival.

Djoumerska-Alexieva I, Roumenina LT, Stefanova T, Vassilev T, Dimitrov JD.

Inflammation. 2017 Feb;40(1):117-122. doi: 10.1007/s10753-016-0460-x.

PMID:
27796617
24.

Endothelial cells: source, barrier, and target of defensive mediators.

Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V.

Immunol Rev. 2016 Nov;274(1):307-329. doi: 10.1111/imr.12479. Review.

PMID:
27782324
25.

Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling.

Kölm R, Schaller M, Roumenina LT, Niemiec I, Kremer Hovinga JA, Khanicheh E, Kaufmann BA, Hopfer H, Trendelenburg M.

J Immunol. 2016 Nov 1;197(9):3669-3679. Epub 2016 Oct 3.

26.

Heme: Modulator of Plasma Systems in Hemolytic Diseases.

Roumenina LT, Rayes J, Lacroix-Desmazes S, Dimitrov JD.

Trends Mol Med. 2016 Mar;22(3):200-213. doi: 10.1016/j.molmed.2016.01.004. Epub 2016 Feb 12. Review.

PMID:
26875449
27.

Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes.

Djoumerska-Alexieva I, Roumenina L, Pashov A, Dimitrov J, Hadzhieva M, Lindig S, Voynova E, Dimitrova P, Ivanovska N, Bockmeyer C, Stefanova Z, Fitting C, Bläss M, Claus R, von Gunten S, Kaveri S, Cavaillon JM, Bauer M, Vassilev T.

Mol Med. 2016 Apr;21(1):1002-1010. doi: 10.2119/molmed.2014.00224. Epub 2016 Mar 31.

28.

A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.

Chauvet S, Roumenina LT, Bruneau S, Marinozzi MC, Rybkine T, Schramm EC, Java A, Atkinson JP, Aldigier JC, Bridoux F, Touchard G, Fremeaux-Bacchi V.

J Am Soc Nephrol. 2016 Jun;27(6):1665-77. doi: 10.1681/ASN.2015040348. Epub 2015 Oct 15.

29.

C3dg-CR3 interaction in erythrophagocytosis.

Roumenina LT.

Blood. 2015 Aug 13;126(7):828-9. doi: 10.1182/blood-2015-07-653428.

30.

Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.

Vasilev VV, Noe R, Dragon-Durey MA, Chauvet S, Lazarov VJ, Deliyska BP, Fremeaux-Bacchi V, Dimitrov JD, Roumenina LT.

J Biol Chem. 2015 Oct 16;290(42):25343-55. doi: 10.1074/jbc.M115.647008. Epub 2015 Aug 5.

31.

Complement System Part I - Molecular Mechanisms of Activation and Regulation.

Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT.

Front Immunol. 2015 Jun 2;6:262. doi: 10.3389/fimmu.2015.00262. eCollection 2015. Review.

32.

Complement System Part II: Role in Immunity.

Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT.

Front Immunol. 2015 May 26;6:257. doi: 10.3389/fimmu.2015.00257. eCollection 2015. Review.

33.

Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.

Rigothier C, Delmas Y, Roumenina LT, Contin-Bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-Bacchi V, Combe C.

Am J Kidney Dis. 2015 Aug;66(2):331-6. doi: 10.1053/j.ajkd.2015.03.039. Epub 2015 May 23.

PMID:
26015278
34.

Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.

Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA.

J Immunol. 2015 Jun 1;194(11):5129-38. doi: 10.4049/jimmunol.1402770. Epub 2015 Apr 27.

35.

Correction to Mechanism and functional implications of the heme-induced binding promiscuity of IgE.

Hadzhieva M, Vassilev TL, Roumenina LT, Bayry J, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD.

Biochemistry. 2015 Apr 14;54(14):2399. doi: 10.1021/acs.biochem.5b00323. Epub 2015 Apr 3. No abstract available.

PMID:
25839915
36.

Mechanism and functional implications of the heme-induced binding promiscuity of IgE.

Hadzhieva M, Vassilev TL, Roumenina LT, Bayry J, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD.

Biochemistry. 2015 Mar 24;54(11):2061-72. doi: 10.1021/bi501507m. Epub 2015 Mar 11. Erratum in: Biochemistry. 2015 Apr 14;54(14):2399.

PMID:
25742488
37.

Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S, Smith RJ, Noris M, Goodship T, Atkinson JP, Fremeaux-Bacchi V.

Blood. 2015 Apr 9;125(15):2359-69. doi: 10.1182/blood-2014-10-609073. Epub 2015 Jan 21.

38.

Loss of DGKε induces endothelial cell activation and death independently of complement activation.

Bruneau S, Néel M, Roumenina LT, Frimat M, Laurent L, Frémeaux-Bacchi V, Fakhouri F.

Blood. 2015 Feb 5;125(6):1038-46. doi: 10.1182/blood-2014-06-579953. Epub 2014 Dec 10.

39.

Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?

Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C, Smith RJ, Noris M, Halbwachs-Mecarelli L, Donadelli R, Fremeaux-Bacchi V, Roumenina LT.

J Am Soc Nephrol. 2014 Sep;25(9):2053-65. doi: 10.1681/ASN.2013070796. Epub 2014 Mar 20.

40.

Anti-factor H autoantibodies assay.

Dragon-Durey MA, Blanc C, Roumenina LT, Poulain N, Ngo S, Bordereau P, Frémeaux-Bacchi V.

Methods Mol Biol. 2014;1100:249-56. doi: 10.1007/978-1-62703-724-2_20.

PMID:
24218265
41.

Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).

Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-Durey MA, Frémeaux-Bacchi V.

Methods Mol Biol. 2014;1100:237-47. doi: 10.1007/978-1-62703-724-2_19.

PMID:
24218264
42.

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status.

Rayes J, Roumenina LT, Dimitrov JD, Repessé Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Frémeaux-Bacchi V, Lacroix-Desmazes S.

Blood. 2014 Jan 2;123(1):121-5. doi: 10.1182/blood-2013-04-495853. Epub 2013 Sep 6.

43.

Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.

Békássy ZD, Kristoffersson AC, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, Hue C, Fremeaux-Bacchi V, Karpman D.

Nephrol Dial Transplant. 2013 Nov;28(11):2899-907. doi: 10.1093/ndt/gft340. Epub 2013 Sep 5.

PMID:
24009284
44.

Antibody polyreactivity in health and disease: statu variabilis.

Dimitrov JD, Planchais C, Roumenina LT, Vassilev TL, Kaveri SV, Lacroix-Desmazes S.

J Immunol. 2013 Aug 1;191(3):993-9. doi: 10.4049/jimmunol.1300880. Review.

45.

Physiological and therapeutic complement regulators in kidney transplantation.

Roumenina LT, Zuber J, Frémeaux-Bacchi V.

Curr Opin Organ Transplant. 2013 Aug;18(4):421-9. doi: 10.1097/MOT.0b013e32836370ce. Review.

PMID:
23838647
46.

Complement factor H related proteins (CFHRs).

Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT.

Mol Immunol. 2013 Dec 15;56(3):170-80. doi: 10.1016/j.molimm.2013.06.001. Epub 2013 Jul 3. Review.

47.

An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.

Hebecker M, Alba-Domínguez M, Roumenina LT, Reuter S, Hyvärinen S, Dragon-Durey MA, Jokiranta TS, Sánchez-Corral P, Józsi M.

J Immunol. 2013 Jul 15;191(2):912-21. doi: 10.4049/jimmunol.1300269. Epub 2013 Jun 14.

48.

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT.

Blood. 2013 Jul 11;122(2):282-92. doi: 10.1182/blood-2013-03-489245. Epub 2013 May 21.

49.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G.

Nat Rev Nephrol. 2012 Nov;8(11):643-57. doi: 10.1038/nrneph.2012.214. Epub 2012 Oct 2. Review.

PMID:
23026949
50.

Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.

Blanc C, Roumenina LT, Ashraf Y, Hyvärinen S, Sethi SK, Ranchin B, Niaudet P, Loirat C, Gulati A, Bagga A, Fridman WH, Sautès-Fridman C, Jokiranta TS, Frémeaux-Bacchi V, Dragon-Durey MA.

J Immunol. 2012 Oct 1;189(7):3528-37. Epub 2012 Aug 24.

Supplemental Content

Loading ...
Support Center